Symbols

AGIO

Agios·NASDAQ

--(--)

AGIO fundamentals

AGIO Q4 2025 Earnings

Agios (AGIO) released its earnings on Feb 12, 2026: revenue was 19.97M (YoY +86.61%), beat estimates; EPS was -1.86 (YoY -29.17%), beat estimates.

Revenue / YoY

19.97M

+86.61%

EPS / YoY

-1.86

-29.17%

Report date

Feb 12, 2026

AGIO Earnings Call Summary for Q4,2025

Revenue Growth: Q4 2025 U.S. PK deficiency revenue of $16 million, up 86% YoY, with 2026 guidance of $45-50 million.
Thalassemia Launch Momentum: 44 AQVESME prescriptions in first 5 weeks, targeting 10-12 week treatment initiation timeline.
Pipeline Catalysts: Phase II Tebapivat data in sickle cell disease (H2 2026) and MDS (H1 2026), plus AG-236/AG-181 early-stage trials.
Financial Strength: $1.2 billion cash balance supports disciplined spending and growth initiatives.
Strategic Focus: Maximize U.S. thalassemia launch while advancing PK activators into high-value indications.

Earnings

EPS

Revenue

Revenue & Expenses

AGIO has released its 2025 Q4 earnings report, with revenue of 19.97M, reflecting a YoY change of 86.09%, and net profit of -108.04M, showing a YoY change of -11.93%. The Sankey diagram below clearly presents AGIO's revenue sources and cost distribution.

Key Indicators

Agios (AGIO) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Agios (AGIO)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Agios (AGIO)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Agios (AGIO)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown